Komsu Mamuya, MD
Cardiovascular Disease · Wethersfield, CTNPI 1073588695
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Amgen at 52.3% of the total. Reporting peaked in 2019 at $8,579 and has fallen 60.7% since, to $3,372 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $54.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Abbott$2K
- Johnson & Johnson$2K
- Novo Nordisk$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Pfizer$668
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$8,90036%
- Travel & lodging$9754%
- Food & beverage$14,82460%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 81 | $12,944 |
| Abbott | 28 | $2,092 |
| Johnson & Johnson | 59 | $1,638 |
| Novo Nordisk | 26 | $1,100 |
| E.r. Squibb & Sons, L.L.C. | 48 | $1,067 |
| Pfizer | 28 | $668 |
| Novartis | 25 | $637 |
| Boston Scientific | 5 | $598 |
| Boehringer Ingelheim | 39 | $568 |
| Merck | 17 | $406 |
| Alnylam Pharmaceuticals Inc. | 8 | $347 |
| Impulse Dynamics (USA) Inc. | 3 | $255 |
| AstraZeneca | 13 | $242 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $191 |
| Bridgebio Pharma, Inc. | 3 | $180 |
| Scpharmaceuticals Inc. | 10 | $166 |
| Heartflow, Inc. | 3 | $163 |
| Actelion Pharmaceuticals US, Inc. | 7 | $159 |
| Lexicon Pharmaceuticals, Inc. | 6 | $156 |
| Bracco Diagnostics Inc. | 1 | $144 |
| Sanofi-aventis U.S. LLC | 6 | $138 |
| Lilly USA, LLC | 5 | $136 |
| Biotronik Inc. | 1 | $112 |
| Bayer | 4 | $102 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $98 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| Esperion Therapeutics, Inc. | 3 | $67 |
| Amarin Pharma, Inc. | 4 | $64 |
| Baxter Healthcare | 1 | $46 |
| Atricure, Inc. | 1 | $30 |
| Philips North America LLC | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Angiodynamics, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $20 |
| Preventice Services, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$9,924
- Assurity Pacemaker$908
- XARELTO$726
- OPTIMIZER$439
- CARDIOMEMS$436
- WATCHMAN Access System$394
- Ozempic$371
- JOT DX$244
- VYNDAQEL$236
- WATCHMAN FLX$149
- GALLANT$145
- LUMASON$144
- Attruby$126
- JARDIANCE$123
- ELIQUIS$122
- AMVUTTRA$121
- ENTRESTO$113
- Edora 8 DR-T$112
- BioMonitor$112
- Rivacor 7 DR-T$112
How this compares
$24,748 in reported general payments places this provider in the 90th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 925 | $1,307,073 |
| FarxigaDapagliflozin Propanediol | 376 | $385,229 |
| JardianceEmpagliflozin | 371 | $358,949 |
| XareltoRivaroxaban | 233 | $340,535 |
| OzempicSemaglutide | 111 | $133,978 |
| Repatha SureclickEvolocumab | 89 | $112,700 |
| EntrestoSacubitril/Valsartan | 79 | $97,386 |
| MultaqDronedarone Hcl | 11 | $22,550 |
| Praluent PenAlirocumab | 16 | $20,117 |
| DapagliflozinDapagliflozin Propanediol | 26 | $16,982 |
| Metoprolol Succinate | 1,116 | $16,664 |
| BrilintaTicagrelor | 13 | $10,704 |
| Atorvastatin Calcium | 902 | $8,969 |
| Rosuvastatin Calcium | 554 | $6,834 |
| VascepaIcosapent Ethyl | 15 | $6,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $668 | $1,307,073925 claims |
| AstraZenecaFarxiga, Brilinta | $242 | $395,934389 claims |
| Boehringer IngelheimJardiance | $568 | $358,949371 claims |
| Johnson & JohnsonXarelto | $1,638 | $340,535233 claims |
| Novo NordiskOzempic | $1,100 | $133,978111 claims |
| NovartisEntresto | $637 | $97,38679 claims |
| Sanofi-aventis U.S. LLCMultaq | $138 | $22,55011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Wethersfield
- Ahmed ElwanWethersfield$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.